Watts Gwilliam & Co’s BioLineRX BLRX Stock Holding History

Watts Gwilliam & Co’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-850	Closed	-$5.44K	–	214
2024 Q4	$5.44K	Buy	+850	New	+$12.5K	﹤0.01%	211

Other funds holding BLRX

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Watts Gwilliam & Co's BLRX Position: Q1 2025 in Review

Watts Gwilliam & Co sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 850 shares — an estimated $5.44K sold.

Watts Gwilliam & Co first reported a position in BLRX in Q4 2024 and held it in 1 quarter. The position peaked at $5.44K in Q4 2024. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.

Watts Gwilliam & Co reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
Watts Gwilliam & Co sold 850 BioLineRX shares in Q1 2025, an estimated $5.44K.
Watts Gwilliam & Co first reported a position in BioLineRX in Q4 2024 and held it in 1 quarter.
Watts Gwilliam & Co's BioLineRX position peaked at $5.44K in Q4 2024.
12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.

Based on Watts Gwilliam & Co's 13F filing for Q1 2025, filed 13 May 2025.